citric acid, anhydrous has been researched along with Ache in 19 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Participants in a population-based colorectal cancer screening program using the fecal immunochemical test who were scheduled for a colonoscopy from 09:00 a." | 6.80 | Ascorbic acid PEG-2L is superior for early morning colonoscopies in colorectal cancer screening programs: a prospective non-randomized controlled trial. ( Balaguer, F; Carballal, S; Cárdenas, A; Castells, A; del Manzano, S; Fernández-Esparrach, G; Ginés, A; González-Suárez, B; Grau, J; Llach, J; López-Cerón, M; Moreira, L; Ordás, I; Pellisé, M; Pozo, A; Ricart, E; Rodríguez de Miguel, C; Sendino, O; Serradesanferm, A; Ubré, M; Vaquero, EC, 2015) |
| "Meta-analysis approaches were used to aggregate evidence identified via the conducted systematic literature review." | 3.01 | A Systematic Literature Review of Injection Site Pain Perception in Adult Patients Treated with Citrate-Free and Citrate-Containing Biologic Agents. ( Bartsch, R; Ebert, O; Junker, S, 2023) |
| "Participants in a population-based colorectal cancer screening program using the fecal immunochemical test who were scheduled for a colonoscopy from 09:00 a." | 2.80 | Ascorbic acid PEG-2L is superior for early morning colonoscopies in colorectal cancer screening programs: a prospective non-randomized controlled trial. ( Balaguer, F; Carballal, S; Cárdenas, A; Castells, A; del Manzano, S; Fernández-Esparrach, G; Ginés, A; González-Suárez, B; Grau, J; Llach, J; López-Cerón, M; Moreira, L; Ordás, I; Pellisé, M; Pozo, A; Ricart, E; Rodríguez de Miguel, C; Sendino, O; Serradesanferm, A; Ubré, M; Vaquero, EC, 2015) |
| "The notification of serious adverse events occurring resulting from the collection of blood or blood components is a statutory requirement." | 2.46 | [Serious adverse effects of blood collection]. ( Danic, B; Lefort, C, 2010) |
| "Urolithiasis is one of the commonest problems in pediatric nephrology." | 1.36 | Clinical manifestations and etiology of renal stones in children less than 14 years age. ( Heidari, A; Sepahi, MA; Shajari, A, 2010) |
| " The total incidence of acute and mild adverse effects (chills and/or fever, paraesthesias, allergic reactions, acute anaemia, vasovagal reactions, abdominal pain and hypotension) was 18." | 1.27 | Adverse effects secondary to the treatment with plasma exchange. ( Castillo, R; Mazzara, R; Puig, L; Torras, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (36.84) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, J | 1 |
| Hong, G | 1 |
| Mazaleuskaya, L | 1 |
| Hsu, JC | 1 |
| Rosario-Berrios, DN | 1 |
| Grosser, T | 1 |
| Cho-Park, PF | 1 |
| Cormode, DP | 1 |
| Chabra, S | 1 |
| Gill, BJ | 1 |
| Gallo, G | 1 |
| Zhu, D | 1 |
| Pitou, C | 1 |
| Payne, CD | 1 |
| Accioly, A | 1 |
| Puig, L | 2 |
| Junker, S | 1 |
| Ebert, O | 1 |
| Bartsch, R | 1 |
| Rodríguez de Miguel, C | 1 |
| Serradesanferm, A | 1 |
| López-Cerón, M | 1 |
| Carballal, S | 1 |
| Pozo, A | 1 |
| Balaguer, F | 1 |
| Cárdenas, A | 1 |
| Fernández-Esparrach, G | 1 |
| Ginés, A | 1 |
| González-Suárez, B | 1 |
| Moreira, L | 1 |
| Ordás, I | 1 |
| Ricart, E | 1 |
| Sendino, O | 1 |
| Vaquero, EC | 1 |
| Ubré, M | 1 |
| del Manzano, S | 1 |
| Grau, J | 1 |
| Llach, J | 1 |
| Castells, A | 1 |
| Pellisé, M | 1 |
| Sepahi, MA | 1 |
| Heidari, A | 1 |
| Shajari, A | 1 |
| Danic, B | 1 |
| Lefort, C | 1 |
| Takakuwa, O | 1 |
| Oguri, T | 1 |
| Maeno, K | 1 |
| Yokoyama, M | 1 |
| Hijikata, H | 1 |
| Uemura, T | 1 |
| Ozasa, H | 1 |
| Ohkubo, H | 1 |
| Miyazaki, M | 1 |
| Niimi, A | 1 |
| VECCHIET, L | 1 |
| MARRA, N | 1 |
| NISHI, A | 1 |
| Laursen, T | 1 |
| Hansen, B | 1 |
| Fisker, S | 1 |
| Martineau, L | 1 |
| Dosch, HM | 1 |
| Boga, C | 1 |
| Kozanoglu, I | 1 |
| Yeral, M | 1 |
| Bakar, C | 1 |
| Harrison, A | 1 |
| Isenberg, JI | 1 |
| Schapira, M | 1 |
| Hagie, L | 1 |
| McKiernan, J | 1 |
| Johnston, DI | 1 |
| Hiller, EJ | 1 |
| Geppetti, P | 1 |
| Tramontana, M | 1 |
| Del Bianco, E | 1 |
| Fusco, BM | 1 |
| Solomons, CC | 1 |
| Melmed, MH | 1 |
| Heitler, SM | 1 |
| Salter, MW | 1 |
| Henry, JL | 1 |
| Schaffler, K | 1 |
| Reeh, PW | 1 |
| Zentzis, K | 1 |
| Hamperl, W | 1 |
| Mazzara, R | 1 |
| Torras, A | 1 |
| Castillo, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects[NCT04259346] | Phase 1 | 245 participants (Actual) | Interventional | 2020-02-05 | Completed | ||
| A Randomized Study to Investigate Injection-Site Pain Following Subcutaneous Injections of 2 Ixekizumab Test Formulations Compared to the Commercial Formulation Using a Pre-filled Syringe in Healthy Subjects[NCT03848403] | Phase 1 | 70 participants (Actual) | Interventional | 2019-01-29 | Terminated (stopped due to At the protocol-specified interim analysis, the sponsor decided to stop the trial.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PK: Cmax of ixekizumab was evaluated (NCT04259346)
Timeframe: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
| Intervention | micrograms per milliliter (ug/mL) (Geometric Mean) |
|---|---|
| 80 mg Ixekizumab (Reference) | 9.66 |
| 80 mg Ixekizumab (Test) | 9.97 |
Area under the plasma concentration versus time curve from time zero to the last measured concentration value (AUC[0-tlast]). AUC 0-tlast is equal to AUC (0-85) days where the last time point was 85 Days ± 3 Days. (NCT04259346)
Timeframe: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
| Intervention | microgram*day/milliliter (ug*day/mL) (Geometric Mean) |
|---|---|
| 80 mg Ixekizumab (Reference) | 207 |
| 80 mg Ixekizumab (Test) | 219 |
Area under the plasma concentration versus time curve from zero to infinity (AUC[0-∞]) of a single dose of Ixekizumab. (NCT04259346)
Timeframe: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
| Intervention | ug*day/mL (Geometric Mean) |
|---|---|
| 80 mg Ixekizumab (Reference) | 213 |
| 80 mg Ixekizumab (Test) | 227 |
The injection pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. The severity of pain was categorized by VAS pain score as: no pain (0), mild pain ≤ 30, moderate pain (>30 and ≤70), and severe pain (>70). Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain). (NCT03848403)
Timeframe: Day 1, 8, and 15: Immediately (within 1 minute) after injection
| Intervention | millimeter (mm) (Mean) |
|---|---|
| Ixekizumab (Reference) | 25.3 |
| Ixekizumab (Test 1) | 3.3 |
| Ixekizumab (Test 2) | 4.1 |
2 reviews available for citric acid, anhydrous and Ache
| Article | Year |
|---|---|
A Systematic Literature Review of Injection Site Pain Perception in Adult Patients Treated with Citrate-Free and Citrate-Containing Biologic Agents.
Topics: Adult; Biological Factors; Biological Products; Citric Acid; Excipients; Humans; Injection Site Reac | 2023 |
[Serious adverse effects of blood collection].
Topics: Anticoagulants; Arteries; Blood Component Removal; Blood Donors; Citric Acid; Hematoma; Humans; Inci | 2010 |
6 trials available for citric acid, anhydrous and Ache
| Article | Year |
|---|---|
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
Topics: Antibodies, Monoclonal, Humanized; Area Under Curve; Citric Acid; Cross-Over Studies; Humans; Inject | 2022 |
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
Topics: Antibodies, Monoclonal, Humanized; Area Under Curve; Citric Acid; Cross-Over Studies; Humans; Inject | 2022 |
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
Topics: Antibodies, Monoclonal, Humanized; Area Under Curve; Citric Acid; Cross-Over Studies; Humans; Inject | 2022 |
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
Topics: Antibodies, Monoclonal, Humanized; Area Under Curve; Citric Acid; Cross-Over Studies; Humans; Inject | 2022 |
Ascorbic acid PEG-2L is superior for early morning colonoscopies in colorectal cancer screening programs: a prospective non-randomized controlled trial.
Topics: Aged; Ascorbic Acid; Cathartics; Citrates; Citric Acid; Colonoscopy; Colorectal Neoplasms; Defecatio | 2015 |
Pain perception after subcutaneous injections of media containing different buffers.
Topics: Adult; Buffers; Citric Acid; Double-Blind Method; Female; Histidine; Human Growth Hormone; Humans; I | 2006 |
Most patients with active symptomatic duodenal ulcers fail to develop ulcer-type pain in response to gastroduodenal acidification.
Topics: Adult; Aged; Citrates; Citric Acid; Double-Blind Method; Duodenal Ulcer; Humans; Hydrochloric Acid; | 1982 |
Capsaicin-desensitization to the human nasal mucosa selectively reduces pain evoked by citric acid.
Topics: Administration, Intranasal; Adolescent; Adult; Analysis of Variance; Capsaicin; Citrates; Citric Aci | 1993 |
Analgesic effect of acetylsalicylic acid (ASA) versus a lithium-ASA combination: an evoked potential study employing radiant heat stimulation with a CO2 laser.
Topics: Adult; Analgesia; Arousal; Aspirin; Carbon Dioxide; Citrates; Citric Acid; Double-Blind Method; Drug | 1987 |
11 other studies available for citric acid, anhydrous and Ache
| Article | Year |
|---|---|
Ultrasmall Antioxidant Cerium Oxide Nanoparticles for Regulation of Acute Inflammation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Biocompatible Materia | 2021 |
Clinical manifestations and etiology of renal stones in children less than 14 years age.
Topics: Adolescent; Child; Child, Preschool; Citric Acid; Cystinuria; Dysuria; Female; Fever; Genetic Predis | 2010 |
Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.
Topics: Administration, Cutaneous; Analgesics, Opioid; Citric Acid; Fentanyl; Humans; Lung Neoplasms; Neopla | 2013 |
[Analytic study of tissue-algogenic reactive phenomena after the intradermal injection of nitric, hydrochloric, sulfuric, lactic, oxalic and citric acids].
Topics: Acids; Citric Acid; Humans; Injections, Intradermal; Pain; Skin; Sulfur | 1960 |
[THE CLINICAL AND EXPERIMENTAL STUDIES ON THE CITRIC ACID METABOLISM IN EKIRI-LIKE SYNDROME].
Topics: Animals; Blood Chemical Analysis; Child; Citrates; Citric Acid; Diarrhea; Diarrhea, Infantile; Dipht | 1963 |
Biofilm reduction by a new burn gel that targets nociception.
Topics: Acetic Acid; Acrylic Resins; Administration, Topical; Anti-Bacterial Agents; Biofilms; Burns; Chelat | 2007 |
Assessment of corrected QT interval in sickle-cell disease patients who undergo erythroapheresis.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Calcium; Citric Acid; Cytapheresis; Electrocardiography; Ery | 2007 |
Patterns of acid-induced release endogenous immunoreactive secretin in children with cystic fibrosis and recurrent pain.
Topics: Abdomen; Adolescent; Child; Child, Preschool; Citrates; Citric Acid; Cystic Fibrosis; Humans; Pain; | 1981 |
Calcium citrate for vulvar vestibulitis. A case report.
Topics: Administration, Oral; Adult; Antacids; Citrates; Citric Acid; Female; Humans; Hyperoxaluria; Pain; P | 1991 |
Effects of adenosine 5'-monophosphate and adenosine 5'-triphosphate on functionally identified units in the cat spinal dorsal horn. Evidence for a differential effect of adenosine 5'-triphosphate on nociceptive vs non-nociceptive units.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Animals; Cats; Citrates; Citric Acid; Neurons, Affe | 1985 |
Adverse effects secondary to the treatment with plasma exchange.
Topics: Abdomen; Adolescent; Adult; Aged; Child; Citric Acid; Female; Fever; Glucose; Humans; Hypersensitivi | 1985 |